---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000525"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:09:15.038544+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals secures exclusive US/Canada rights to Diabetinol®; 1M shares and royalty

## Summary
- Exclusive rights to Diabetinol® in US & Canada; nutraceutical for blood glucose/HbA1c management.
- Consideration: 1M restricted shares (~16% dilution) plus 10% net sales revenue.
- Term perpetual; if <$1.5M sales by Dec 2026, rights become non-exclusive; can extend 12 mo with $5M payment.
- Raised $200k via sale of 80k shares at $2.50/share to accredited investor.
- Clinical study: 14.3% reached HbA1c targets (vs 0% placebo); 83.3% reached SBP goals (vs 60%).

## SEC filing metadata
- accession: 0001641172-25-000525
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/0001641172-25-000525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000525
- JSON: https://secwatch.observer/filing/0001641172-25-000525.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.